Delving into the Latest Updates on Docetaxel with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

BEIZRAY, DEP® docetaxel, Docetaxel Hydrate

+ [59]

Target

Tubulin

Action

inhibitors

Mechanism

Tubulin inhibitors

Therapeutic Areas

NeoplasmsDigestive System DisordersEndocrinology and Metabolic Disease+ [3]

Active Indication

Early Stage Breast CarcinomaGastroesophageal junction adenocarcinomaMetastatic castration-resistant prostate cancer+ [37]

Inactive Indication

AdenocarcinomaAdenocarcinoma of EsophagusAdenocarcinoma of prostate+ [116]

Originator Organization

Sanofi

Active Organization

AstraZeneca PLC

Hospira, Inc.

Sanofi Winthrop Industrie SA

+ [23]

Inactive Organization

Teva Pharmaceuticals Europe BV

Sanofi

Pfizer Inc.

+ [29]

License Organization

Sanofi (China) Investment Co. Ltd.The General Hospital Corp.

Lumos Pharma, Inc.

+ [8]

Drug Highest PhaseApproved

First Approval Date

European Union (27 Nov 1995),

Breast CancerHead and Neck NeoplasmsNon-Small Cell Lung Cancer+ [2]

RegulationAccelerated Approval (United States), Priority Review (China)

Login to view timeline

Structure/Sequence

Molecular FormulaC43H55NO15

InChIKeyYWKYKORYUFJSCV-XKIQGVRMSA-N

CAS Registry148408-66-6

Doctors leading this study would like to learn about providing cancer treatment/therapies to Nigerian women with breast cancer based on their human epidermal growth factor receptor 2 (HER2) status. This study will focus on the efficacy and safety of anti-HER2 cancer treatment before and after surgery.

Start Date01 Jan 2026

Sponsor / Collaborator

The University of Chicago

NCT05296005

/ WithdrawnPhase 1IIT

Total Neoadjuvant Therapy for the Treatment of Gastroesophageal Junction (GEJ) and Gastric Cancers: A Pilot Trial

This phase I trial tests the safety, side effects studies chemotherapy followed by chemotherapy at the same time as radiation therapy (chemoradiation) before surgery (neoadjuvant) in treating patients with stage gastric (stomach) or gastroesophageal junction cancer . Chemotherapy drugs, such as docetaxel, oxaliplatin , leucovorin, fluorouracil, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy and chemoradiation before surgery may make the tumor smaller and may reduce the amount of normal tissue that needs to be removed.

Start Date31 Dec 2025

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

100 Clinical Results associated with Docetaxel

Login to view more data

100 Translational Medicine associated with Docetaxel

Login to view more data

100 Patents (Medical) associated with Docetaxel

Login to view more data

31,290

Literatures (Medical) associated with Docetaxel

31 Dec 2025·INTERNATIONAL JOURNAL OF HYPERTHERMIA

Cisplatin + docetaxel improves survival over cisplatin + mitomycin C in hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective study based on propensity score matching

Article

Author: Yu, Yang ; Fu, Yu-Bin ; Ma, Ru ; Yang, Rui ; Li, Yan ; Wei, Tian ; Li, Bing ; Su, Yan-Dong

OBJECTIVE:

Pseudomyxoma peritoneum (PMP) of appendiceal origin poses significant treatment challenges with hyperthermic intraperitoneal chemotherapy (HIPEC) regimens offering viable outcomes. This study aimed to compare the efficacy and safety profiles of two HIPEC regimens: cisplatin + docetaxel (CD) and cisplatin + mitomycin C (CM).

METHODS:

PMP patients who underwent cytoreductive surgery (CRS) and HIPEC between January 2008 and December 2023 at our center were retrospectively analyzed. Patients were divided into CD and CM groups and matched for baseline characteristics using propensity score matching (PSM). Clinicopathological data, efficacy, and safety profiles were compared. Univariate and multivariate analyses identified independent prognostic factors, and subgroup analyses further compared the two regimens.

RESULTS:

After PSM, 104 patients met the inclusion criteria (52 in each group). The median overall survival (mOS) was significantly longer in the CD group (156.3 vs. 60.9 months, p = 0.018), with no significant differences in adverse event severity between groups. Multivariate analysis identified HIPEC regimen, completeness of cytoreduction (CC), and pathological type as independent prognostic factors. Subgroup analysis showed significant mOS benefit for the CD regimen in patients with peritoneal carcinomatosis index (PCI) ≥ 27, CC 2/3, high grade pathology, tumor markers ≥1 evaluated and BMI < 25 (all p < 0.005).

CONCLUSIONS:

Following CRS, the CD regimen offers superior survival benefits compared to the CM regimen for PMP patients. These findings highlight the potential of personalized HIPEC strategies to optimize outcomes for PMP treatment.

31 Dec 2025·Human Vaccines & Immunotherapeutics

Cost-effectiveness of trastuzumab deruxtecan as a second-line treatment for HER2-mutant advanced non-small cell lung cancer

Article

Author: You, Shuhui ; Gong, Caifeng ; Cai, Qi ; Zhang, Wen ; Huang, Jinglong ; Zhou, Aiping

The study of DESTINY-Lung01 and DESTINY-Lung02 demonstrated the favorable efficacy and optimal dosage of trastuzumab deruxtecan (T-DXd) in managing the human epidermal growth factor receptor 2 (HER2)-mutant non-small cell lung cancer (NSCLC) patients who had received previous treatment. The study sought to assess the cost-effectiveness of T-DXd in both the United States (US) and Chinese healthcare systems. Markov models were developed to evaluate the overall cost, incremental cost-effectiveness ratio (ICER), quality-adjusted life years (QALYs), and life years (LYs) of treatment with T-DXd compared with docetaxel, nivolumab, and pyrotinib for patients in the US and China. The level of willingness-to-pay (WTP) in the US and China is 150,000/QALYs and 32,517/QALYs, respectively. Sensitivity analyses were carried out to ensure the precision of the model. T-DXd yielded additional QALYs of 0.63 and 0.06 with an ICER of $338997.84 and $1437258.33 per QALY, respectively, in the US compared to the docetaxel and nivolumab regimens. And T-DXd yielded additional QALYs of 0.63, 0.06, and 0.13 with an ICER of $137959.45, $623805.93, and $515447.12 per QALY, respectively, in China compared to the docetaxel, nivolumab, and pyrotinib regimens. Sensitivity analysis showed that the cost of drugs is the most influential factor. T-DXd provides substantial therapeutic benefit for NSCLC patients with HER2 mutations who have had previous treatment but is not deemed cost-effective in either the US or China when compared to docetaxel, nivolumab, and pyrotinib. Price reduction is perhaps the main way to make T-DXd cost-effective.

01 Dec 2025·Journal of Gastrointestinal Cancer

Correlation Between Histopathological Response of Esophageal Squamous Cell Carcinoma to Neoadjuvant DCF Therapy and the Clinical Efficacy of Palliative Chemotherapy for Recurrence

Article

Author: Yamamoto, Shun ; Honma, Yoshitaka ; Kato, Ken ; Igaue, Shota ; Daiko, Hiroyuki ; Ishiyama, Koshiro ; Kurita, Daisuke ; Shiraishi, Kazuhiro ; Itoyama, Mai ; Yokoyama, Kazuki ; Imazeki, Hiroshi ; Oguma, Junya ; Kashihara, Tairo

BACKGROUND:

Docetaxel-cisplatin-5-fluorouracil (DCF) is a new standard neoadjuvant therapy for locally advanced esophageal squamous cell carcinoma (ESCC) in Japan. However, some patients experience recurrence and require further systemic platinum-containing chemotherapy. It is unclear whether such regimens are appropriate after a poor histopathological response to neoadjuvant DCF.

METHODS:

Data were retrospectively collected on patients with recurrence of ESCC treated with palliative chemotherapy after neoadjuvant DCF at our institution between February 2014 and June 2022. We defined patients with a grade 0-1 histopathological response as insufficient responders (IRs) and those with grade 2-3 as good responders (GRs). The correlation between the histopathological response and the response to palliative chemotherapy was investigated.

RESULTS:

Thirty-two patients (median age 63.5 years, range 46-76) were included. Performance status was 0 in 12 (37.5%), 1 in 16 (50.0%), and 2 in 4 (12.5%). Histopathological response grades 0/1/2/3 were 3.1%/68.7%/21.9%/6.3%, respectively. Platinum-containing chemotherapy was administered to 13 patients (56.5%) in the IR group and 9 (100%) in the GR group. The overall response rate was 34.8%, and median progression-free survival was 2.431 months in the IR group and 44.4% and 4.041 months, respectively, in the GR group. Multivariate analysis identified a chemotherapy-free interval of < 6 months as an independent prognostic factor (HR 4.096, 95% CI 1.116-15.037) but not the histopathological response (HR 1.137, 95% CI 0.309-4.177).

CONCLUSIONS:

Histopathological response to neoadjuvant DCF therapy did not affect the efficacy of first-line chemotherapy for recurrent ESCC.

1,065

News (Medical) associated with Docetaxel

31 Jul 2025

·www.prnewswire.com

Akeso Announces Completion of First Dosing in Phase III Clinical Trial of Ivonescimab (PD-1/VEGF) Combination Therapy for Immunotherapy-Resistant NSCLC

HONG KONG, July 30, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its pivotal Phase III clinical study (AK112-305/HARMONi-8A) of ivonescimab (PD-1/VEGF bispecific antibody) in combination with docetaxel for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) that has progressed following PD-1/L1 inhibitors and platinum-based chemotherapy. Ivonescimab is the only bispecific immunotherapy antibody currently undergoing Phase III registration trials for IO-resistant lung cancer. In recent years, immunotherapy has achieved significant progress in the treatment of NSCLC. PD-1/L1 inhibitors, whether used as monotherapy or in combination with platinum-based chemotherapy, have become the standard first-line treatment for advanced NSCLC in patients without driver mutations. However, despite these advances, 60%-70% of patients experience disease progression within the first year of treatment. Currently, there are no approved standard treatment options for IO-resistant NSCLC. Docetaxel is recommended in both China's and international treatment guidelines for immunotherapy-resistant (IO-resistant) NSCLC. However, docetaxel's monotherapy efficacy in the IO-resistant NSCLC patients remains limited. Several Phase III clinical trials investigating IO-resistant lung cancer, including immunotherapy combination therapies studies and ADC therapy studies, have failed to demonstrate positive results. Mechanistic studies suggest that PD-1 therapy can restore the immune system's anti-tumor activity, while anti-VEGF therapy alleviates VEGF-mediated immune suppression and promotes T-cell infiltration. When combined, these two therapies may produce synergistic effects. Ivonescimab simultaneously targets both PD-1 and VEGF pathways, reversing the immune-suppressive tumor microenvironment and reactivating anti-tumor immune responses. These synergistic mechanisms provide a scientific rationale for using ivonescimab to treat IO-resistant tumors. Furthermore, the positive efficacy and safety data demonstrated in a Phase II study in this indication underscore the significant therapeutic potential of ivonescimab in this difficult to treat patient population. The ivonescimab regimen has demonstrated remarkable efficacy and excellent safety across multiple tumor types. The ongoing AK112-305/HARMONi-8A Phase III study targeting IO-resistant NSCLC is expected to offer a novel and highly effective treatment option for patients with IO-resistant NSCLC, in line Akesos ' 'Immuno-2.0' strategy. As the world's leading PD-1/VEGF bispecific antibody, ivonescimab has achieved extensive population coverage for core indications in NSCLC and is positioned across multiple lines of treatment, with the potential to reshape the overall treatment landscape for advanced NSCLC. Forward-Looking Statement of Akeso, Inc. This announcement by Akeso, Inc. (9926.HK, "Akeso") contains "forward-looking statements". These statements reflect the current beliefs and expectations of Akeso's management and are subject to significant risks and uncertainties. These statements are not intended to form the basis of any investment decision or any decision to purchase securities of Akeso. There can be no assurance that the drug candidate(s) indicated in this announcement or Akeso's other pipeline candidates will obtain the required regulatory approvals or achieve commercial success. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in P.R.China, the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Akeso's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the Akeso's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. Akeso does not undertake any obligation to publicly revise these forward-looking statements to reflect events or circumstances after the date hereof, except as required by law. About Akeso Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world's first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 24 candidates have entered clinical trials (including 15 bispecific/multispecific antibodies and bispecific ADCs. Additionally, 7 new drugs are commercially available, and 2 new drugs with 2 new indications are under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise. For more information, please visit and follow us on Linkedin. SOURCE Akeso, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 3ImmunotherapyClinical ResultPhase 2

30 Jul 2025

·www.fiercebiotech.com

GSK\'s anti-TIM-3 antibody flunks phase 3 trial as anti-TIGIT failure costs $629M

GSK may not have been surprised its anti-TIM-3 drug couldn’t secure a phase 3 win based on how its pharma peers have struggled.\n GSK’s cobolimab has become the latest anti-TIM-3 antibody to flunk a crucial oncology test, as the pharma absorbs a more than $600 million hit from its anti-TIGIT drug failure.The British Big Pharma had been evaluating cobolimab—which it acquired in the $5.1 billion Tesaro takeover in 2018—in various combinations with oncology med Jemperli and the chemotherapy docetaxel in a phase 3 study of 750 patients with non-small cell lung cancer (NSCLC).The company revealed in its second-quarter earnings this morning that the study didn’t reach its primary endpoint of improving overall survival in advanced NSCLC after prior immuno-oncology therapies.“All regimens were well-tolerated and toxicities were consistent with known safety profiles of docetaxel and immune checkpoint inhibitors,” GSK said in its July 30 earnings release (PDF). “This remains a challenging treatment setting where novel combinations have yet to improve outcomes for most patients.”The late-stage fail doesn\'t mark the end of GSK\'s hopes for cobolimab. The company is still evaluating the drug in a phase 1/2 trial in a range of pediatric cancer settings as well as in a midstage trial for advanced liver cancer.TIM-3 is expressed by immune effector cells, where it acts as an immune checkpoint, and leukemic stem cells, leading various Big Pharmas to identify the receptor as a way to simultaneously activate the immune system and suppress the proliferation of cancer cells.GSK may not have been surprised that cobolimab couldn’t secure a phase 3 win. The drug was the most advanced anti-TIM-3 antibody left standing after Novartis’ own candidate failed a late-stage study in patients with myelodysplastic syndrome or leukemia at the start of 2024.While Novartis focused on blood cancers, GSK and other big names with TIM-3 candidates had largely looked at solid tumors. Roche removed (PDF) a PD-1xTIM-3 bispecific from its pipeline in 2022, while Bristol Myers Squibb terminated a phase 1 trial of a TIM-3 candidate, BMS-986299, in 2022 because its “business objectives” had changed. Eli Lilly and Incyte have also axed their respective TIM-3 drugs. AstraZeneca appears to still have a foot in the anti-TIM-3 space, with a PD-1xTIM-3 bispecific that is due to complete a phase 1/2 study this year.TIM-3 wasn’t the only high-risk cancer target where GSK crashed and burned this quarter. The pharma revealed in the same earnings document that its decision to end development of the anti-TIGIT antibody belrestotug had resulted in a 471 million pound sterling ($629 million) impairment charge.GSK paid iTeos $625 million upfront for the rights to belrestotug four years ago. In the wake of belrestotug’s phase 2 failure, the biotech initially planned to wind down operations before accepting a buyout offer from Concentra Biosciences earlier this month.This morning’s release also revealed that GSK has discontinued a phase 2-stage adjuvanted recombinant protein vaccine for malaria dubbed GSK3437949. A spokesperson for the company put this move in the context of the pharma’s recently announced push into second-generation, multistage malaria vaccines.Meanwhile, sanfetrinem cilexetil—an oral prodrug of the antibiotic sanfetrinem—has been removed from the company’s phase 2 pipeline after having “not compared favourably in early studies to existing treatments and other tuberculosis-specific assets also in development at GSK,” the spokesperson said.

VaccinePhase 3Phase 1AcquisitionPhase 2

30 Jul 2025

·endpoints.news

GSK reaffirms goal of bringing Blenrep to US, reports fail with TIM-3 inhibitor

GSK CEO Emma Walmsley said the company is steadfast in bringing Blenrep back to the US market after several FDA setbacks. In its second-quarter earnings report Wednesday, the company also revealed a Phase 3 trial of various combinations featuring its anti-TIM-3 antibody, called cobolimab, had failed. Walmsley said in a media call GSK is “very confident in the Blenrep data, and really pleased that we have an updated PDUFA date.” She added that “we are in constructive dialogue with the agency: answering questions, providing some additional data.” GSK has previously said Blenrep could reach £3 billion ($4 billion) a year in global sales in second-line multiple myeloma. Last week, the FDA extended its review of Blenrep by around three months after an advisory committee largely voted against the risk-benefit profiles of two separate combinations including the drug for second-line disease. The agency now has until Oct. 23 to make a decision. During the meeting, committee members raised their concerns over the fact that just 5% of patients included in Blenrep’s clinical development were from the US, as well as the limited enrollment of African American patients. “The representation of our studies was consistent with other studies for approved multiple myeloma indications in the US designed as global registrational studies,” Walmsley said on the call. “We did have a significant profile of European countries, but all of the demographics and outcomes in those countries are also consistent with the US.” This is GSK’s second attempt to get Blenrep past the finish line. The medicine was originally greenlit in 2020 under an accelerated approval pathway, but the company voluntarily pulled it from the US market in 2022 after it flunked a confirmatory trial. The drug was approved in Europe last week. Elsewhere in its oncology pipeline, the UK drugmaker’s Phase 3 trial of its anti-TIM-3 antibody cobolimab in doublet or triplet combinations with Jemperli and docetaxel in non-small cell lung cancer ended in failure last month. The study missed its primary endpoint of improving overall survival in pretreated patients. GSK also removed two programs from Phase 2 development: A recombinant protein codenamed GSK3437949 for malaria, and a serine beta-lactamase inhibitor called sanfetrinem cilexetil for tuberculosis. The malaria drop comes as the company is shifting its focus to second-generation vaccines for the disease, a spokesperson told Endpoints News in an email. The tuberculosis asset “has not compared favourably in early studies to existing treatments,” they said. Elsewhere, Walmsley said that GSK is in dialogue with the Trump administration on how to “keep the US leading the world in terms of being a market for innovation, and to make sure that we are passing on the discounts that we provide to patients.” She declined to provide further details of the talks, but noted the company “would like to see all countries investing more and recognizing the value more that [healthcare] innovation brings.” Walmsley is the latest big pharma CEO, along with AstraZeneca’s Pascal Soriot and Roche’s Thomas Schinecker , to mention discussions with the Trump administration on US drug prices. The UK pharma’s Q2 sales came in 2% ahead of Wall Street consensus estimates at £8 billion ($10.7 billion). The success was largely driven by GSK’s vaccines franchise, which saw sales increase 9% from the same period last year to £2.1 billion ($2.8 billion). In particular, the £853 million in sales for shingles vaccine Shingrix were buoyed by launch uptake in France and continued demand in other European markets and Japan. GSK’s share price is up 1.5% on the London Stock Exchange.

Phase 3VaccinePhase 2Drug ApprovalAccelerated Approval

100 Deals associated with Docetaxel

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D07866	Docetaxel	L01CD02	DB01248

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Early Stage Breast Carcinoma	European Union	Accord Healthcare SLU	22 May 2012
Early Stage Breast Carcinoma	Iceland	Accord Healthcare SLU	22 May 2012
Early Stage Breast Carcinoma	Liechtenstein	Accord Healthcare SLU	22 May 2012
Early Stage Breast Carcinoma	Norway	Accord Healthcare SLU	22 May 2012
Gastroesophageal junction adenocarcinoma	European Union	Fresenius Kabi Deutschland GmbH	22 May 2012
Gastroesophageal junction adenocarcinoma	Iceland	Fresenius Kabi Deutschland GmbH	22 May 2012
Gastroesophageal junction adenocarcinoma	Liechtenstein	Fresenius Kabi Deutschland GmbH	22 May 2012
Gastroesophageal junction adenocarcinoma	Norway	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	European Union	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	European Union	Accord Healthcare SLU	22 May 2012
Metastatic castration-resistant prostate cancer	Iceland	Accord Healthcare SLU	22 May 2012
Metastatic castration-resistant prostate cancer	Iceland	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	Liechtenstein	Accord Healthcare SLU	22 May 2012
Metastatic castration-resistant prostate cancer	Liechtenstein	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	Norway	Fresenius Kabi Deutschland GmbH	22 May 2012
Metastatic castration-resistant prostate cancer	Norway	Accord Healthcare SLU	22 May 2012
Metastatic gastric adenocarcinoma	European Union	Accord Healthcare SLU	22 May 2012
Metastatic gastric adenocarcinoma	Iceland	Accord Healthcare SLU	22 May 2012
Metastatic gastric adenocarcinoma	Liechtenstein	Accord Healthcare SLU	22 May 2012
Metastatic gastric adenocarcinoma	Norway	Accord Healthcare SLU	22 May 2012

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Castration-sensitive prostate cancer	Phase 3	United Kingdom	Novartis AG	11 Jun 2024
Advanced Lung Non-Small Cell Carcinoma	Phase 3	China	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	08 Jun 2023
Hormone-dependent prostate cancer	Phase 3	Austria	Bayer AG	16 May 2023
Hormone-dependent prostate cancer	Phase 3	Germany	Bayer AG	16 May 2023
Advanced Malignant Solid Neoplasm	Phase 3	India	Zhuhai Beihai Biotechnology Co., Ltd.	29 Apr 2021
Solid tumor	Phase 3	India	Zhuhai Beihai Biotechnology Co., Ltd.	29 Apr 2021
Circulating Neoplastic Cells	Phase 3	United Kingdom	Sanofi	11 Jan 2017
Metastatic Prostate Carcinoma	Phase 3	United Kingdom	Sanofi	11 Jan 2017
HER2 Positive Breast Cancer	Phase 3	United States	Hoffmann-La Roche, Inc.	14 Mar 2016
HER2 Positive Breast Cancer	Phase 3	China	Hoffmann-La Roche, Inc.	14 Mar 2016

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


TRINIGAST (ESMO_GI2025)	Not Applicable	Malignant neoplasm of gastro-oesophageal junction HER2-negative \| MSS \| CPS ≥5 ... View more	-	DCFm (docetaxel, cisplatin, 5-FU) plus nivolumab	bptfjceouv(saynwrsrew) = lywxsooumc vyanxzzmne (qphmkipxyl ) View more	Positive	03 Jul 2025
NCT06732531 (Phase 1 study of intravesical BH011 in HR-NMIBC after BCG failure, ASCO2025)	Phase 1	Non-Muscle Invasive Bladder Neoplasms	6	BH011 17.5mg	puwnotteku(rlpkeajaaz) = No BH011-related serious adverse events (AEs) occurred zdraukiohw (junnzzvkas ) View more	Positive	30 May 2025
CTRI/2017/05/008700 (DHANUSH, ASCO2025)	Phase 2/3	Head and Neck Neoplasms cisplatin-ineligible	356	Concurrent Docetaxel + Radiation Therapy	jhcmgabnkv(boaheclzey) = ckjnfhkzwf qitjjeqxia (wkyqrrcauy, 29.9 - 44.1) View more	Positive	30 May 2025
				Radiation Therapy Alone	jhcmgabnkv(boaheclzey) = ssyvedogqu qitjjeqxia (wkyqrrcauy, 17.7 - 30.3) View more
NCT00288080 (NRG/RTOG 0521, ASCO2025)	Phase 3	Localized Prostate Carcinoma Adjuvant	350	Docetaxel + Standard of Care (RT+ADT)	qybrgivocy(kejbxdycmh) = bvrdebiaak rtsbjwdgjm (wgnqscxtlp )	Positive	30 May 2025
				docetaxel (Standard of Care (RT+ADT))	qybrgivocy(kejbxdycmh) = cwobjnqlbx rtsbjwdgjm (wgnqscxtlp )
NCT06732531 (BH011, ASCO2025)	Phase 1/2	Carcinoma in situ of uterine cervix \| Non-Muscle Invasive Bladder Neoplasms	25	BH011 17.5mg	ertyzoqpbs(zkqlakypfl) = ilcdaqgckz ylsbnhunok (ibdewsooag ) View more	Positive	30 May 2025
ASCO2025	Not Applicable	-	696	Early Docetaxel Therapy	gvfyqfftyi(lswoqerzai) = dhppawuohy zusjezmjfw (khqjpjvqtn ) View more	Positive	30 May 2025
				Delayed Docetaxel Therapy	gvfyqfftyi(lswoqerzai) = cymgmvdjtg zusjezmjfw (khqjpjvqtn ) View more
ASCO2025	Not Applicable	Breast Cancer Adjuvant Her2 neu negative	-	Doxorubicin/cyclophosphamide combined with paclitaxel (ACT)	kixltxachm(dwoathttnm) = rixjkkjxyi linuiprvob (mkqxsxfpok ) View more	Negative	30 May 2025
				Docetaxel/cyclophosphamide (TC)	kixltxachm(dwoathttnm) = xoxlthalkz linuiprvob (mkqxsxfpok ) View more
AACR2025	Not Applicable	Soft Tissue Sarcoma Second line CRP \| neutrophil-lymphocyte-ratio \| platelet-lymphocyte-ratio ... View more	74	Gemcitabine-docetaxol-cisplatin with everolimus (G-GTC/E)	zdoubflxdo(simgyystgi) = oordngnfxi oyijbbufbz (kkirocapom ) View more	Positive	30 Apr 2025
NCT02512315 (Pubmed)	Phase 3	Nasopharyngeal Carcinoma Neoadjuvant	186	Neoadjuvant chemotherapy plus concurrent chemoradiotherapy	mwsbqthzct(lkqhyrgdop) = iqlkxmqwzq ejuebejwov (myjhiwgqcb, 84.2 - 96.4)	Positive	15 Apr 2025
				Concurrent chemoradiotherapy only	mwsbqthzct(lkqhyrgdop) = ibjueuyzwk ejuebejwov (myjhiwgqcb, 75.0 - 90.2)
NCT03264547 (EMERALD, Pubmed \| J Clin Oncol)	Phase 3	HER2 Positive Breast Cancer First line HER2+	446	Eribulin + Trastuzumab-Pertuzumab	swhhrzdxev(oelqshxmkm) = iccnqwivnw cnxsmehoxz (hojgrwtidl )	Positive	10 Apr 2025
				Taxane + Trastuzumab-Pertuzumab	swhhrzdxev(oelqshxmkm) = borjveyrvw cnxsmehoxz (hojgrwtidl )